Pharmacological Interventions in Post-Traumatic Stress Disorder

Post-traumatic stress disorder (PTSD) is a disabling psychiatric condition triggered by exposure to life-threatening or profoundly distressing events. First-line pharmacotherapy typically involves selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), which aim to restore dysregulated monoaminergic transmission and ameliorate core symptoms such as intrusive memories, hyperarousal and avoidance. For patients who fail to respond, second-line options include prazosin for trauma-related nightmares, atypical antipsychotics to target comorbid agitation and insomnia, and off-label agents such as anticonvulsants. Recent attention has centred on interventions that modulate memory processes directly—enhancing fear extinction or disrupting pathological reconsolidation. Glucocorticoids administered shortly after trauma may attenuate memory consolidation, while NMDA-receptor modulators and cannabinoids are being explored to augment exposure-based therapies. Emerging compounds such as ketamine, MDMA and endocannabinoid modulators have shown promise for treatment-resistant cases, with preliminary studies reporting rapid symptom relief and durable gains when combined with psychotherapy. Advances in understanding the hypothalamic-pituitary-adrenal axis and neuroplasticity have driven a shift towards personalised approaches, integrating pharmacological agents to optimise timing, dosage and mechanistic synergy with behavioural interventions. This expanding pharmacopeia reflects a move from purely symptom-based prescribing towards tailored strategies that address the neurobiological underpinnings of trauma memory, resilience and recovery.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Interventions in Post-Traumatic Stress Disorder publication trend

The graph below shows the total number of articles in pharmacological interventions in post-traumatic stress disorder across all publications each year (not limited to Nature Index journals).

Technical terms

Selective serotonin reuptake inhibitors (SSRIs): Antidepressants that increase serotonin availability in synaptic clefts by blocking its reabsorption into presynaptic neurons.

Glucocorticoids: Steroid hormones released by the adrenal cortex that influence stress responses, memory consolidation and inflammatory processes.

Fear extinction: The learning process through which conditioned fear responses decrease when a feared stimulus is repeatedly presented without adverse outcomes.

Reconsolidation: A restabilisation phase during which reactivated memories can be modified, offering a window for therapeutic interventions that weaken traumatic recollections.

Glucocorticoid receptor antagonist: A compound that binds to and inhibits the receptor for glucocorticoids, potentially disrupting maladaptive memory processes.

References

1. Current and novel pharmacological therapeutic approaches in Post-Traumatic Stress Disorder. A brief review. Acta Marisiensis - Seria Medica (2021).
2. Corticosterone enhances formation of non-fear but not fear memory during infectious illness. Frontiers in Behavioral Neuroscience (2023).
3. Progress in Personalized Psychiatric Therapy with the Example of Using Intranasal Oxytocin in PTSD Treatment. Journal of Personalized Medicine (2022).
4. Three Prospective Case Studies Examining Mifepristone’s Efficacy in Patients with Treatment‐Resistant PTSD. Case Reports in Psychiatry (2024).